PMID- 20431310
OWN - NLM
STAT- MEDLINE
DCOM- 20100817
LR  - 20151119
IS  - 1423-0240 (Electronic)
IS  - 0378-584X (Linking)
VI  - 33 Suppl 4
DP  - 2010
TI  - [HER2 testing and targeted therapy in advanced gastric cancer].
PG  - 26-30
LID - 10.1159/000308451 [doi]
AB  - A large phase III study on the use of the HER2 antibody trastuzumab in locally 
      advanced or metastatic gastric cancer has now been completed. Patients whose 
      tumors were either scored on immunohistochemistry (IHC) as 3+ (independently of 
      the result of fluorescence in situ hybridization (FISH)) or as IHC2+ and FISH+ 
      were found, in a planned subgroup analysis, to have a median overall survival 
      time of 16.0 months--versus 11.8 months when trastuzumab was not given. In light 
      of these data, trastuzumab was therefore approved by the European Medicines 
      Agency (EMEA) for metastasizing patients with this HER2 test result. It should be 
      noted that the IHC scoring system for gastric cancer was modified compared to 
      that for breast cancer. If the same criteria as are used for breast cancer were 
      used for gastric cancer, this would lead to a large number of false negatives; 
      around half of the patients who would benefit from trastuzumab would not be 
      identified. Workshops for pathologists and round robin tests are being carried 
      out to introduce the new scoring system.
FAU - Hohler, Thomas
AU  - Hohler T
AD  - Medizinische Klinik I, Prosper-Hospital, Recklinghausen, Deutschland.
FAU - Ruschoff, Josef
AU  - Ruschoff J
FAU - Ridwelski, Karsten
AU  - Ridwelski K
FAU - Moehler, Markus
AU  - Moehler M
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - HER2-Diagnostik und zielgerichtete Therapie beim fortgeschrittenen Magenkarzinom.
DEP - 20100423
PL  - Switzerland
TA  - Onkologie
JT  - Onkologie
JID - 7808556
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Adenocarcinoma/*drug therapy/*genetics/mortality/pathology
MH  - Aged
MH  - Algorithms
MH  - Antibodies, Monoclonal/*administration & dosage/adverse effects
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse 
      effects
MH  - Biopsy
MH  - Clinical Trials, Phase III as Topic
MH  - Drug Approval
MH  - *Drug Delivery Systems
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Neoplasm Invasiveness
MH  - Neoplasm Staging
MH  - Practice Guidelines as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Receptor, ErbB-2/*genetics
MH  - Stomach/pathology
MH  - Stomach Neoplasms/*drug therapy/*genetics/mortality/pathology
MH  - Survival Rate
MH  - Trastuzumab
EDAT- 2010/05/07 06:00
MHDA- 2010/08/18 06:00
CRDT- 2010/05/01 06:00
PHST- 2010/05/01 06:00 [entrez]
PHST- 2010/05/07 06:00 [pubmed]
PHST- 2010/08/18 06:00 [medline]
AID - 000308451 [pii]
AID - 10.1159/000308451 [doi]
PST - ppublish
SO  - Onkologie. 2010;33 Suppl 4:26-30. doi: 10.1159/000308451. Epub 2010 Apr 23.